CTXR Quote, Financials, Valuation and Earnings

Merck & has a net margin of -- compared to Citius Pharmaceuticals's net margin of 18.95%. Citius Pharmaceuticals's return on equity of -- beat Merck &'s return on equity of 29.26%.

Citius Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 879.9%. On the other hand Merck & has an analysts' consensus of $130.34 which suggests that it could grow by 29.84%. Given that Citius Pharmaceuticals has higher upside potential than Merck &, analysts believe Citius Pharmaceuticals is more attractive than Merck &.

Citius Pharmaceuticals has a beta of 1.302, which suggesting that the stock is 30.18% more volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.15% to investors and pays a quarterly dividend of $0.81 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Citius Pharmaceuticals's net income of -$10.8M is lower than Merck &'s net income of $3.2B. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 3.99x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Citius Pharmaceuticals's net margin of -49.65%. Citius Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Citius Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 879.9%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that Citius Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Citius Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Citius Pharmaceuticals has a beta of 1.302, which suggesting that the stock is 30.18% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Citius Pharmaceuticals's net income of -$10.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nuvalent has a net margin of -- compared to Citius Pharmaceuticals's net margin of --. Citius Pharmaceuticals's return on equity of -- beat Nuvalent's return on equity of --.

Citius Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 879.9%. On the other hand Nuvalent has an analysts' consensus of $115.08 which suggests that it could grow by 42.46%. Given that Citius Pharmaceuticals has higher upside potential than Nuvalent, analysts believe Citius Pharmaceuticals is more attractive than Nuvalent.

Citius Pharmaceuticals has a beta of 1.302, which suggesting that the stock is 30.18% more volatile than S&P 500. In comparison Nuvalent has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Nuvalent pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Nuvalent quarterly revenues of --. Citius Pharmaceuticals's net income of -$10.8M is higher than Nuvalent's net income of -$84.3M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Nuvalent's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus -- for Nuvalent. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Citius Pharmaceuticals's net margin of -2357.27%. Citius Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Citius Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 879.9%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than Citius Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Citius Pharmaceuticals.

Citius Pharmaceuticals has a beta of 1.302, which suggesting that the stock is 30.18% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Citius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Citius Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Citius Pharmaceuticals's net income of -$10.8M is lower than Palatin Technologies's net income of -$7.8M. Notably, Citius Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.